Loading clinical trials...

A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | Clinical Trials | Clareo Health

WITHDRAWN

A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer

NCT04148378•ProgenaBiome

Summary

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding colorectal cancer.

Detailed Description

The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding colorectal cancer.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
•2. Male or female patients of any age (interest is given to children to compare with mothers).
•3. Diagnosis of colorectal cancer

Exclusion Criteria

•1. Refusal to sign informed consent form
•2. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
•3. Postoperative stoma, ostomy, or ileoanal pouch
•4. Participation in any experimental drug protocol within the past 12 weeks
•5. Treatment with total parenteral nutrition
•6. Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial
•7. Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study

Locations (1)

ProgenaBiome

Ventura, California, United States

Key Dates

Start Date

March 2, 2020

Primary Completion Date

March 1, 2030

Completion Date

July 1, 2030

Last Updated

June 5, 2025

Conditions

Colorectal CancerColorectal NeoplasmsColorectal CarcinomaColorectal AdenocarcinomaColorectal Cancer MetastaticColorectal Sarcoma

Interventions

No intervention

OTHER

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors